Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $13.00

Stoke Therapeutics (NASDAQ:STOK) had its target price boosted by JPMorgan Chase & Co. from $6.00 to $13.00 in a report issued on Tuesday, Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms have also issued reports on STOK. Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a buy rating in a research note on Tuesday. Needham & Company LLC reaffirmed a buy rating and issued a $14.00 price objective on shares of Stoke Therapeutics in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $19.63.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $13.50 on Tuesday. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.40. The firm has a market cap of $625.05 million, a price-to-earnings ratio of -5.70 and a beta of 0.68. The firm’s 50 day moving average price is $6.07 and its two-hundred day moving average price is $5.02.

Insiders Place Their Bets

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at $126,550.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at approximately $423,035. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,615 shares of company stock valued at $212,852. 12.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Ensign Peak Advisors Inc bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $25,000. Point72 Hong Kong Ltd bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $27,000. Great West Life Assurance Co. Can boosted its holdings in shares of Stoke Therapeutics by 46.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock worth $28,000 after buying an additional 1,078 shares during the period. UBS Group AG bought a new stake in shares of Stoke Therapeutics during the 3rd quarter worth about $47,000. Finally, Quantbot Technologies LP boosted its holdings in shares of Stoke Therapeutics by 207.1% during the 1st quarter. Quantbot Technologies LP now owns 4,300 shares of the company’s stock worth $90,000 after buying an additional 2,900 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.